Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 64, Number 3, February 08, 2005
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beydoun, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beydoun, A.
Related Collections
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
Right arrowRelated Article
NEUROLOGY 2005;64:475-480
© 2005 American Academy of Neurology

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

A. Beydoun, MD, B. M. Uthman, MD, A. R. Kugler, PhD, M. J. Greiner, MPH, L. E. Knapp, PharmD, E. A. Garofalo, MD and the Pregabalin 1008–009 Study Group

From the University of Michigan Health System (Dr. Beydoun) and Pfizer Global Research and Development (Drs. Kugler, Knapp, and Garofalo, M.J. Greiner), Ann Arbor Laboratories, Pfizer Inc., Ann Arbor, MI, and North Florida/South Georgia Veterans Health System and University of Florida College of Medicine and McKnight Brain Institute (Dr. Uthman), Gainesville, FL.

Address correspondence and reprint requests to Dr. A. Beydoun, University of Michigan Health System, 1500 E. Medical Center Dr., UH 1 B 300/0036, Ann Arbor, MI 48109-0036; e-mail: beydoun{at}umich.edu

Objective: To evaluate the efficacy, tolerability, and safety of two pregabalin regimens administered as adjunctive therapy to that of placebo in patients with medically refractory partial epilepsy.

Methods: A multicenter, double-blind, randomized, parallel-group, placebo-controlled trial was performed. Following a prospective 8-week baseline phase, patients were randomized to 12 weeks of double-blind treatment with placebo or pregabalin 600 mg/day administered twice daily (BID) or three times daily (TID). Primary efficacy was measured as change in seizure frequency from baseline of either pregabalin regimen compared with placebo. Secondary efficacy comparisons included the proportion of patients experiencing ≥50% reduction in seizure frequency (responder rate) and median percentage change from baseline in seizure frequency. Safety/tolerability assessments included adverse events (AEs), physical and neurologic examinations, and clinical laboratory evaluation. Efficacy and safety analyses were performed on the intent-to-treat (ITT) population.

Results: Pregabalin treatment resulted in seizure frequency reductions: 53% for pregabalin TID (p ≤ 0.0001) and 44% for pregabalin BID (p ≤ 0.0001) compared with a 1% increase for placebo. Responder rates were 49% for pregabalin TID and 43% for pregabalin BID compared with 9% for placebo (p ≤ 0.001). Both pregabalin regimens were similar in efficacy and tolerability. The most common AEs were dizziness, somnolence, and ataxia.

Conclusions: Pregabalin administered at 600 mg/day is safe, generally well tolerated, and efficacious as adjunctive therapy for the treatment of patients with partial seizures, with or without secondary generalizations. This dose can be administered on a twice daily or three times daily schedule with similar efficacy and tolerability results.

Supported by Pfizer Inc.

Received January 17, 2003. Accepted in final form October 22, 2004.


Related Article

February 8 Highlights
Neurology 2005 64: 404-405. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
D. Nutt, F. Mandel, and F. Baldinetti
Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model
J Psychopharmacol, November 1, 2009; 23(8): 867 - 873.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
M. L. Blommel and A. L. Blommel
Pregabalin: An antiepileptic agent useful for neuropathic pain
Am. J. Health Syst. Pharm., July 15, 2007; 64(14): 1475 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. J. Siddall, M. J. Cousins, A. Otte, T. Griesing, R. Chambers, and T. K. Murphy
Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial
Neurology, November 28, 2006; 67(10): 1792 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. F Shneker and J. W McAuley
Pregabalin: A New Neuromodulator with Broad Therapeutic Indications
Ann. Pharmacother., December 1, 2005; 39(12): 2029 - 2037.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.